ClinicalTrials.Veeva

Menu

Tranexamic Acid in Hip Fracture Surgery

S

Spectrum Health Hospitals

Status

Completed

Conditions

Hip Fracture

Study type

Observational

Funder types

Other

Identifiers

NCT02736383
2016-060

Details and patient eligibility

About

To determine if TXA utilization is effective at reducing transfusion rates in elderly patients undergoing surgery for treatment of a hip fractures.

Enrollment

142 patients

Sex

All

Ages

65+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Acute, isolated, unilateral femoral neck, intertrochanteric, and per trochanteric hip fractures confirmed by anteroposterior/lateral hip radiographs, computed tomography, or magnetic resonance imaging.
  • Age 65 and older
  • Low energy mechanism of injury
  • Hip fracture fixation performed within 48 hours
  • English speaking
  • Anticipated medical optimization for operative fixation
  • No other major trauma

Exclusion criteria

  • Retained hardware around the affected hip
  • Infection around the affected hip
  • Transfer patients with a length of stay > 24 hours at the transferring hospital
  • Diagnosis of deficient natural anticoagulation
  • Known congenital thrombophilia (Deficiency of Protein C, S, Antithrombin)
  • Known allergy to TXA
  • Patients undergoing percutaneous pinning of the hip fracture

Trial design

142 participants in 2 patient groups

Tranexamic Acid
Description:
Patients that receive 2 gm TXA during surgery
No Tranexamic Acid
Description:
Patients that receive no TXA during surgery

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems